Consistent with this hypothesis, Hanrahan et al. have reported that the genetic and functional analysis of ovarian cancer cell lines and tumors, mutational status of PIK3CA or PTEN alone may not be sufficient in predicting sensitivity to AKT inhibitors [60]. This evidence concerns the gene PIK3CA and ovarian carcinoma.